{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:13:51Z","timestamp":1787688831825,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Suez Canal University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rift Valley Fever Virus (RVFV) is an arbovirus, a zoonotic disease that resurfaces as a potential hazard beyond geographic boundaries. Fever that can proceed to encephalitis, retinitis, hemorrhagic fever, and death is the main manifestation observed in human infections. RVFV has no authorized medication. The RNA interference (RNAi) gene silencing pathway is extremely well conserved. By targeting specific genes, small interfering RNA (siRNA) can be used to suppress viral replication. The aim of this study was to design specific siRNAs against RVFV and evaluate their prophylactic and antiviral effects on the Vero cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>Various siRNAs were designed using different bioinformatics tools. Three unique candidates were tested against an Egyptian sheep cell culture-adapted strain BSL-2 that suppressed RVFV N mRNA expression. SiRNAs were transfected a day before RVFV infection (pre-transfection), and 1\u00a0h after the viral infection (post-transfection), and were evaluated to detect the silencing activity and gene expression decrease using real-time PCR and a TCID50 endpoint test. The degree of N protein expression was determined by western blot 48\u00a0h after viral infection. D2 which targets the (488\u2013506 nucleotides), the middle region of RVFV N mRNA was the most effective siRNA at 30 nM concentration, it almost eliminates N mRNA expression when utilized as antiviral or preventive therapy. siRNAs had a stronger antiviral silencing impact when they were post-transfected into Vero cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pre and post-transfection of siRNAs significantly reduced RVFV titer in cell lines, offering novel and potentially effective anti-RVFV epidemics and epizootics therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11033-023-08455-9","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:02:01Z","timestamp":1685030521000},"page":"5837-5848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiviral and protective effect of small interfering RNAs against rift valley fever virus in vitro"],"prefix":"10.1007","volume":"50","author":[{"given":"Engy. M.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer. A.","family":"Boseila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-9847","authenticated-orcid":false,"given":"Amro S.","family":"Hanora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar. M.","family":"Solyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"8","key":"8455_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/tmi.12108","volume":"18","author":"O Dar","year":"2013","unstructured":"Dar O, Hogarth S, McIntyre S (2013) Tempering the risk: Rift Valley fever and bioterrorism. Trop Med Int Health 18(8):1036\u20131041","journal-title":"Trop Med Int Health"},{"issue":"6","key":"8455_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/vetres\/2010033","volume":"41","author":"M Pepin","year":"2010","unstructured":"Pepin M et al (2010) Rift valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41(6):61","journal-title":"Vet Res"},{"issue":"2","key":"8455_CR3","doi-asserted-by":"publisher","first-page":"e0005383","DOI":"10.1371\/journal.pntd.0005383","volume":"11","author":"OA Hassan","year":"2017","unstructured":"Hassan OA et al (2017) The One Health approach to identify knowledge, attitudes and practices that affect community involvement in the control of Rift Valley fever outbreaks. PLoS Negl Trop Dis 11(2):e0005383","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"8455_CR4","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1016\/S2214-109X(16)30176-0","volume":"4","author":"M Baudin","year":"2016","unstructured":"Baudin M et al (2016) Association of Rift Valley fever virus infection with miscarriage in sudanese women: a cross-sectional study. Lancet Glob Health 4(11):e864\u2013e871","journal-title":"Lancet Glob Health"},{"key":"8455_CR5","doi-asserted-by":"crossref","unstructured":"Fawzy M, Helmy YA (2019) The One Health Approach is necessary for the control of Rift Valley Fever Infections in Egypt: a Comprehensive Review.Viruses, 11(2)","DOI":"10.3390\/v11020139"},{"issue":"1","key":"8455_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12917-017-0993-8","volume":"13","author":"C Mroz","year":"2017","unstructured":"Mroz C et al (2017) Seroprevalence of Rift Valley fever virus in livestock during inter-epidemic period in Egypt, 2014\/15. BMC Vet Res 13(1):87","journal-title":"BMC Vet Res"},{"issue":"10","key":"8455_CR7","doi-asserted-by":"publisher","first-page":"19506","DOI":"10.2807\/ese.15.10.19506-en","volume":"15","author":"V Chevalier","year":"2010","unstructured":"Chevalier V et al (2010) Rift Valley fever\u2013a threat for Europe? Euro Surveill 15(10):19506","journal-title":"Euro Surveill"},{"issue":"14","key":"8455_CR8","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","volume":"89","author":"T Ikegami","year":"2015","unstructured":"Ikegami T et al (2015) Rift Valley Fever Virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments. J Virol 89(14):7262\u20137276","journal-title":"J Virol"},{"issue":"6669","key":"8455_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806\u2013811","journal-title":"Nature"},{"issue":"6836","key":"8455_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494\u2013498","journal-title":"Nature"},{"issue":"5","key":"8455_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0092-8674(02)00908-X","volume":"110","author":"J Martinez","year":"2002","unstructured":"Martinez J et al (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110(5):563\u2013574","journal-title":"Cell"},{"key":"8455_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ceb.2018.02.011","volume":"52","author":"AH Corbett","year":"2018","unstructured":"Corbett AH (2018) Post-transcriptional regulation of gene expression and human disease. Curr Opin Cell Biol 52:96\u2013104","journal-title":"Curr Opin Cell Biol"},{"issue":"23","key":"8455_CR13","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.3390\/molecules25235771","volume":"25","author":"F F\u00f6ldes","year":"2020","unstructured":"F\u00f6ldes F et al (2020) Small interfering RNAs are highly effective inhibitors of Crimean-Congo Hemorrhagic Fever Virus Replication in Vitro. Molecules 25(23):5771","journal-title":"Molecules"},{"issue":"7","key":"8455_CR14","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1371\/journal.pmed.0030242","volume":"3","author":"DM Dykxhoorn","year":"2006","unstructured":"Dykxhoorn DM, Lieberman J (2006) Silencing viral infection. PLoS Med 3(7):e242","journal-title":"PLoS Med"},{"key":"8455_CR15","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3389\/fmicb.2018.02151","volume":"9","author":"A Levanova","year":"2018","unstructured":"Levanova A, Poranen MM (2018) RNA interference as a prospective Tool for the control of human viral infections. Front Microbiol 9:2151","journal-title":"Front Microbiol"},{"key":"8455_CR16","doi-asserted-by":"crossref","unstructured":"Levanova A (2022) Antiviral potency of small interfering RNA molecules In Hameed S, Rehman S, editors, Nanotechnology for Infectious Diseases., : p. p.\u00a0603\u2013638","DOI":"10.1007\/978-981-16-9190-4_27"},{"key":"8455_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1743-422X-8-249","volume":"8","author":"O Flusin","year":"2011","unstructured":"Flusin O et al (2011) Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Virol J 8:249","journal-title":"Virol J"},{"issue":"6","key":"8455_CR18","doi-asserted-by":"publisher","first-page":"e99764","DOI":"10.1371\/journal.pone.0099764","volume":"9","author":"CF Chiang","year":"2014","unstructured":"Chiang CF et al (2014) Small interfering RNA inhibition of Andes virus replication. PLoS ONE 9(6):e99764","journal-title":"PLoS ONE"},{"issue":"11","key":"8455_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1086\/516786","volume":"195","author":"M Ferres","year":"2007","unstructured":"Ferres M et al (2007) Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis 195(11):1563\u20131571","journal-title":"J Infect Dis"},{"issue":"5","key":"8455_CR20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00705-018-3757-2","volume":"163","author":"PM Villegas","year":"2018","unstructured":"Villegas PM et al (2018) Inhibition of dengue virus infection by small interfering RNAs that target highly conserved sequences in the NS4B or NS5 coding regions. Arch Virol 163(5):1331\u20131335","journal-title":"Arch Virol"},{"key":"8455_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3389\/fmicb.2016.01889","volume":"7","author":"B Faburay","year":"2016","unstructured":"Faburay B, Richt JA (2016) Short interfering RNA inhibits Rift Valley Fever Virus replication and degradation of protein kinase R in human cells. Front Microbiol 7:1889","journal-title":"Front Microbiol"},{"issue":"7552","key":"8455_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature14442","volume":"521","author":"EP Thi","year":"2015","unstructured":"Thi EP et al (2015) Lipid nanoparticle siRNA treatment of Ebola-virus-makona-infected nonhuman primates. Nature 521(7552):362\u2013365","journal-title":"Nature"},{"issue":"2","key":"8455_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1060028014561227","volume":"49","author":"BM Bishop","year":"2015","unstructured":"Bishop BM (2015) Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 49(2):196\u2013206","journal-title":"Ann Pharmacother"},{"issue":"3","key":"8455_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ REED","year":"1938","unstructured":"REED LJ, MUENCH H, A SIMPLE METHOD (1938) OF ESTIMATING FIFTY PER CENT ENDPOINTS12. Am J Epidemiol 27(3):493\u2013497","journal-title":"Am J Epidemiol"},{"key":"8455_CR25","doi-asserted-by":"crossref","unstructured":"Naito Y et al (2006) siVirus: web-based antiviral siRNA design software for highly divergent viral sequences.Nucleic Acids Res, 34(Web Server issue): p.W448-50","DOI":"10.1093\/nar\/gkl214"},{"issue":"3","key":"8455_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds A et al (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22(3):326\u2013330","journal-title":"Nat Biotechnol"},{"issue":"2","key":"8455_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1046-2023(02)00023-3","volume":"26","author":"SM Elbashir","year":"2002","unstructured":"Elbashir SM et al (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26(2):199\u2013213","journal-title":"Methods"},{"key":"8455_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/1471-2105-7-520","volume":"7","author":"JP Vert","year":"2006","unstructured":"Vert JP et al (2006) An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7:520","journal-title":"BMC Bioinformatics"},{"key":"8455_CR29","doi-asserted-by":"crossref","unstructured":"Naito Y et al (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.Nucleic Acids Res, 32(Web Server issue): p.W124-9","DOI":"10.1093\/nar\/gkh442"},{"issue":"2","key":"8455_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1101\/gad.862301","volume":"15","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Lendeckel W, Tuschl T (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15(2):188\u2013200","journal-title":"Genes Dev"},{"issue":"2 Suppl","key":"8455_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4269\/ajtmh.2010.09-0293","volume":"83","author":"AS Anyangu","year":"2010","unstructured":"Anyangu AS et al (2010) Risk factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg 83(2 Suppl):14\u201321","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"8455_CR32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3201\/eid2002.131000","volume":"20","author":"A Sow","year":"2014","unstructured":"Sow A et al (2014) Rift Valley fever outbreak, southern Mauritania, 2012. Emerg Infect Dis 20(2):296\u2013299","journal-title":"Emerg Infect Dis"},{"issue":"2 Suppl","key":"8455_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4269\/ajtmh.2010.09-0291","volume":"83","author":"KM Rich","year":"2010","unstructured":"Rich KM, Wanyoike F (2010) An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg 83(2 Suppl):52\u201357","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"8455_CR34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1089\/vbz.2010.0245","volume":"11","author":"AI Al-Afaleq","year":"2011","unstructured":"Al-Afaleq AI, Hussein MF (2011) The status of Rift Valley fever in animals in Saudi Arabia: a mini review. Vector Borne Zoonotic Dis 11(12):1513\u20131520","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"9","key":"8455_CR35","doi-asserted-by":"publisher","first-page":"e44703","DOI":"10.1371\/journal.pone.0044703","volume":"7","author":"C Maffioli","year":"2012","unstructured":"Maffioli C et al (2012) SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices. PLoS ONE 7(9):e44703","journal-title":"PLoS ONE"},{"issue":"1","key":"8455_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nm1164","volume":"11","author":"V Bitko","year":"2005","unstructured":"Bitko V et al (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11(1):50\u201355","journal-title":"Nat Med"},{"issue":"9","key":"8455_CR37","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1128\/AAC.00014-09","volume":"53","author":"R Alvarez","year":"2009","unstructured":"Alvarez R et al (2009) RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 53(9):3952\u20133962","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"8455_CR38","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1128\/AAC.01368-06","volume":"51","author":"S M\u00fcller","year":"2007","unstructured":"M\u00fcller S, G\u00fcnther S (2007) Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother 51(6):2215\u20132218","journal-title":"Antimicrob Agents Chemother"},{"key":"8455_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1743-422X-6-188","volume":"6","author":"A Alkhalil","year":"2009","unstructured":"Alkhalil A et al (2009) Inhibition of monkeypox virus replication by RNA interference. Virol J 6:188","journal-title":"Virol J"},{"issue":"14","key":"8455_CR40","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518\u20136548","journal-title":"Nucleic Acids Res"},{"key":"8455_CR41","unstructured":"Anjorin M (2019) The use of antimicrobial peptides, LL-37 and derivatives, to target Rift Valley Fever Virus infection.Master of Science Biology. George Mason University, https:\/\/hdl.handle.net\/1920\/11601"},{"issue":"1\u20132","key":"8455_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijpharm.2016.08.056","volume":"513","author":"M Narenji","year":"2016","unstructured":"Narenji M, Talaee MR, Moghimi HR (2016) Investigating the effects of size, charge, viscosity and bilayer flexibility on liposomal delivery under convective flow. Int J Pharm 513(1\u20132):88\u201396","journal-title":"Int J Pharm"},{"issue":"5","key":"8455_CR43","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.0437841100","volume":"100","author":"Q Ge","year":"2003","unstructured":"Ge Q et al (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A 100(5):2718\u20132723","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"8455_CR44","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.1073\/pnas.0402486101","volume":"101","author":"Q Ge","year":"2004","unstructured":"Ge Q et al (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 101(23):8676\u20138681","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8455_CR45","first-page":"101","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B et al (2020) Therapeutic siRNA: state of the art 5(1):101","journal-title":"Therapeutic siRNA: state of the art"},{"issue":"7","key":"8455_CR46","doi-asserted-by":"publisher","first-page":"e21503","DOI":"10.1371\/journal.pone.0021503","volume":"6","author":"DR Caffrey","year":"2011","unstructured":"Caffrey DR et al (2011) siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS ONE 6(7):e21503","journal-title":"PLoS ONE"},{"key":"8455_CR47","doi-asserted-by":"crossref","unstructured":"Whither (2003) RNAi? Nat Cell Biol, 5(6): p.\u00a0489 \u2013 90","DOI":"10.1038\/ncb0603-490"},{"issue":"1","key":"8455_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2004.12.017","volume":"17","author":"K Huppi","year":"2005","unstructured":"Huppi K, Martin SE, Caplen NJ (2005) Defining and assaying RNAi in mammalian cells. Mol Cell 17(1):1\u201310","journal-title":"Mol Cell"},{"key":"8455_CR49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1743-422X-7-270","volume":"7","author":"X Wu","year":"2010","unstructured":"Wu X et al (2010) Inhibitory effect of small interfering RNA on dengue virus replication in mosquito cells. Virol J 7:270","journal-title":"Virol J"},{"issue":"4","key":"8455_CR50","first-page":"63675","volume":"2006","author":"S Oliveira","year":"2006","unstructured":"Oliveira S, Storm G, Schiffelers RM (2006) Targeted delivery of siRNA. J Biomed Biotechnol 2006(4):63675","journal-title":"J Biomed Biotechnol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08455-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:53:48Z","timestamp":1687557228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08455-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["8455"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08455-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors approved the present version for publication purposes and agreed to hold accountability for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}